|The most commonly reported undesirable effects during the clinical trials performed with the paracetamol/tramadol combination were nausea, dizziness and somnolence, observed in more than 10 % of the patients. The frequencies are defined as follows:|
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.
|Very common:Common: Uncommon: Rare: Very rare: Unknown: ||≥1/10
≥1/100 to <1/10≥1/1000 to <1/100≥1/10 000 to <1/1000 <1/10 000Frequency cannot be estimated from the available data|
Cardiac disorders: • Uncommon: palpitations, tachycardia, arrythmia.
Eye disorders:• Rare: vision blurred, miosis, mydriasis
Ear and labyrinth disorders:• Uncommon: tinnitus
Gastro-intestinal disorders: • Very common : nausea • Common: vomiting, constipation, dry mouth, diarrhoea abdominal pain, dyspepsia, flatulence • Uncommon: dysphagia, melaena
General disorders and administration site conditions: • Uncommon: chills, chest pain
Investigations: • Uncommon: transaminases increased
Metabolism and nutrition disorders: • Unknown: hypoglycaemia
Nervous system disorders:• Very common: dizziness, somnolence • Common: headache trembling • Uncommon: involuntary muscular contractions, paraesthesia, amnesia• Rare: ataxia, convulsions, syncope, speech disorders.
Psychiatric disorders: • Common: confusional state, mood altered (anxiety, nervousness, euphoric mood), sleep disorders • Uncommon: depression, hallucination, nightmares, Rare: delirium, drug dependence.
Post marketing surveillancevery rare: abuse.
Renal and urinary disorders:• Uncommon: albuminuria, micturition disorders (dysuria and urinary retention)
Respiratory, thoracic and mediastinal disorders: system disorders: • Uncommon: dyspnoea
Skin and subcutaneous tissue disorders:• Common: hyperhidrosis, pruritus• Uncommon: dermal reactions (e.g. rash, urticaria).
Vascular disorders: • Uncommon : hypertension, hot flushAlthough not observed during clinical trials, the occurrence of the following undesirable effects known to be related to the administration of tramadol or paracetamol cannot be excluded:
Tramadol• Postural hypotension, bradycardia, collapse (tramadol).• Post-marketing surveillance of tramadol has revealed rare alterations of warfarin effect, including elevation of prothrombin times.• Rare cases (≥ 1/10000 to < 1/1000) : allergic reactions with respiratory symptoms (e.g. dyspnoea, bronchospasm, wheezing, angioneurotic oedema) and anaphylaxis• Rare cases (≥ 1/10000 to < 1/1000) : changes in appetite, motor weakness, and respiratory depression• Psychic side-effects may occur following administration of tramadol which vary individually in intensity and nature (depending on personality and duration of medication). These include changes in mood, (usually euphoric mood occasionally dysphoria), changes in activity (usually suppression occasionally increase) and changes in cognitive and sensorial capacity (e.g. decision behaviour perception disorders).• Worsening of asthma has been reported though a causal relationship has not been established.• Symptoms of drug withdrawal syndrome, similar to those occurring during opiate withdrawal may occur as follows: agitation, anxiety, nervousness, insomnia, hyperkinesia, tremor and gastrointestinal symptoms. Other symptoms that have very rarely been seen if tramadol hydrochloride is discontinued abruptly include: panic attacks, severe anxiety, hallucinations, paraesthesia, tinnitus and unusual CNS symptoms.
Paracetamol• Adverse effects of paracetamol are rare but hypersensitivity including skin rash may occur. There have been reports of blood dyscrasias including thrombocytopenia and agranulocytosis, but these were not necessarily causally related to paracetamol.• There have been several reports that suggest that paracetamol may produce hypoprothrombinemia when administered with warfarin-like compounds. In other studies, prothrombin time did not change.• Very rare cases of serious skin reactions have been reported.
Reporting of suspected adverse reactionsReporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions viaHPRA PharmacovigilanceEarlsfort Terrace IRL - Dublin 2Tel: +353 1 6764971Fax: +353 1 6762517Website: www.hpra.iee-mail: firstname.lastname@example.org